Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-arm clinical study on the safety and efficacy of Camrelizumab combined with carboplatin and albumin paclitaxel in the neoadjuvant therapy of potentially resectable stage II-IIIA esophageal squamous cell carcinoma

Next Previous
Search
Trial Profile

A prospective, single-arm clinical study on the safety and efficacy of Camrelizumab combined with carboplatin and albumin paclitaxel in the neoadjuvant therapy of potentially resectable stage II-IIIA esophageal squamous cell carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Oct 2022 Results of post hoc analysis assessing the performance of 18F-FDG PET/CT to predict the pathological response to neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma published in the European Journal of Nuclear Medicine and Molecular Imaging
    • 17 Jan 2021 Status changed from recruiting to active, no longer recruiting, as per Results presented at the 2021 Gastrointestinal Cancers Symposium
    • 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top